Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat 
Standard Chartered Q1 Profit Hits Record on Wealth and Investment Banking Growth 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
Microsoft Azure Growth Forecast Beats Expectations Amid Rising AI Competition 
Alphabet Earnings Surge on AI Growth, Cloud Revenue, and Strong Search Performance 
NAB First-Half Earnings Miss Forecasts Amid Rising Global Risks 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
Apple Q2 2026 Earnings Surge as iPhone 17 Sales Drive Record Revenue 
Middle East Conflict Impacts Australia and New Zealand Businesses 
Supreme Court Asked to Reinstate Mail-Order Access to Abortion Pill Mifepristone 
Anthropic’s $1.5B AI Venture with Wall Street Firms Targets Private Equity Market 
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges 
Meta Raises 2026 Capex Outlook Amid AI Spending Surge, Shares Drop After Earnings 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
Spirit Airlines Shuts Down Flights, Issues Refunds After Financial Collapse 
Coles Group Q3 Sales Rise Driven by Supermarkets and E-Commerce Growth 
BOTHELL, Wash., May 07, 2018 -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced that it will webcast a business overview and update by Paul B. Cleveland, Interim President and Chief Executive Officer, at the 2018 Bank of America Merrill Lynch Health Care Conference at 1:15 p.m. PT on Tuesday, May 15, 2018 in Las Vegas, NV.
A live audio webcast of the event can be accessed on the Events & Presentations page of the Investors section of Alder's website at http://www.alderbio.com, or by following the link below in your web browser. An archived replay of the webcast will be available on Alder's website for at least 30 days after the live event concludes.
About Alder BioPharmaceuticals, Inc.
Alder BioPharmaceuticals is a clinical-stage biopharmaceutical company focused on transforming the migraine treatment paradigm through the discovery, development and commercialization of novel therapeutic antibodies. Alder’s lead product candidate, eptinezumab, is a monoclonal antibody (mAb) that inhibits calcitonin gene-related peptide (CGRP) and is currently in late-stage clinical development for the prevention of migraine. Unlike other CGRP inhibitors, eptinezumab was specifically designed as an infusion therapy to address significant patient need. Alder is also developing ALD1910, a preclinical mAb that inhibits pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38) for migraine prevention. For more information, please visit www.alderbio.com.
Investor Relations Contacts:
Ashwin Agarwal
Vice President, Corporate Strategy
Alder Biopharmaceuticals, Inc.
425-408-8567
[email protected]
Michael Schaffzin
Stern Investor Relations, Inc.
212-362-1200
[email protected]
Media Contact:
Andy Brimmer / Aura Reinhard / Trevor Gibbons
Joele Frank, Wilkinson Brimmer Katcher
212-355-4449
